EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Vir Biotechnology's SWOT analysis: stock poised for growth amid hepatitis breakthroughs By Investing.com
Vir Biotechnology's drugs receive FDA and EMA nods By Investing.com
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc.
Vir Biotechnology Trades Higher in Sympathy with Janux Therapeutics By Investing.com
Victory Capital Management Inc. Acquires 15,696 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs | Morningstar
Company Website: https://www.vir.bio SAN FRANCISCO -- (Bus
Vir Biotechnology's SWOT analysis: stock poised for growth amid clinical progress By Investing.com
HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR)
Head-To-Head Survey: Coherus BioSciences (NASDAQ:CHRS) vs. Vir Biotechnology (NASDAQ:VIR)
Vir Biotechnology poised for outperformance, keeps buy rating on pipeline potential By Investing.com
Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR)
Empowered Funds LLC Decreases Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program | Morningstar
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program By Investing.com
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency By Investing.com
Vir Biotechnology stock hits 52-week low at $7.08 By Investing.com
